This study illustrates the consequences of smallpox revaccination in 45 lepromatous, 28 tuberculoid, and 47 normal individuals. Results obtained with intradermal inoculations indicated that the patients with leprosy were associated with a relative anergy against the vaccinia virus, the anergy being minimal in the tuberculoid leprosy but marked in the cases with lepromatous leprosy. Major vaccinial reactions were observed more often in patients with lepromatous leprosy than in the controls or patients with tuberculoid leprosy. Furthermore in a patient with lepromatous leprosy, vaccinia necrosum also developed. The smallpox vaccination with live virus also appeared as a provocative factor for the precipitation of lepra reaction in the lepromatous leprosy cases. After 3 weeks of vaccination, the frequency of the specific humoral antibody response was the same in the tuberculoid patients and controls while it was higher in the cases with lepromatous leprosy. The prevaccination titer of total hemagglutination inhibition antibody was significantly higher in the lepromatous leprosy cases. However, the postvaccinial, humoral antibody response of the lepromatous patients was of the same magnitude as that observed in the normal individuals, and it was mainly due to a 2-mercaptoethanol-resistant antibody.
It has been recognized that delayed hypersensitivity, or some other aspect of tissue immunity, plays a role as important as circulating antibodies in smallpox immunity (1, 8) . It is also well documented that patients with lepromatous leprosy exhibit a generalized depression of cell-mediated immunity along with hyperactivity of humoral antibody system (21, 23) . There are scattered and unconfirmed reports that infections with vaccinia and rubella viruses tend to be more severe in patients with lepromatous leprosy (4) . Accordingly, studies have been recommended to observe the effect of dose and route of administration of vaccinia virus on the morbidity associated with smallpox vaccination in patients with leprosy (4) . Data relating to the consequences of administration of smallpox vaccine in the various types of leprosy patients are described and discussed in the present study.
MATERIALS AND METHODS Forty-seven normal adults and 73 age-and sexmatched leprosy patients, including 45 lepromatous and 28 tuberculoid type, whose diagnosis was based upon testing with lepromin and skin biopsy (16) formed the basis of this study. Cases with borderline tuberculoid leprosy were included under tuberculoid leprosy whereas patients with borderline lepromatous leprosy were grouped with the lepromatous leprosy cases. All the subjects had received primary vaccination in their childhood. The scar following the primary vaccination was noted in each individual to confirm the history of primary vaccination. Revaccination with vaccinia virus was undertaken in four stages. (i) Twenty-one normal humans and 38 patients with leprosy (consisting of 24 lepromatous and 14 tuberculoid type) were revaccinated at two spots, 2.5 cm apart, on the left arm with freeze-dried U.S.S.R.
vaccine containing 106 pock-forming units (PFU) by multiple puncture method (24) . (ii) Another 8 leprosy patients (including 5 lepromatous and 3 tuberculoid cases) and 16 normal adults were inoculated intradermally with 1 million PFU of live vaccinia virus per 0.1 ml normal saline. (iii) In 27 additional leprosy patients (consisting of 20 lepromatous and 7 tuberculoid patients) and 16 controls, intradermal inoculation was also undertaken with 0.1 ml of normal saline containing 1 million PFU of heat-inactivated vaccinia virus. (iv) Study of acceleration of the vaccinial reactions following successive revaccinations was undertaken in 4 normals and 5 leprosy patients (consisting of 2 lepromatous and 3 tuberculoid individuals). The latter three methods were employed for studying the specific cell-mediated immunity against vaccinia virus (8, 13 11 .0 mm, and 6.4 mm in the controls, tuberculoid, and lepromatous patients, respectively ( Table 3 ). The findings suggest that the leprosy patients were associated with depression of specific cellmediated immunity against vaccinia virus. The depression was more profound in the cases with lepromatous leprosy. The larger indurations observed with the live vaccine might be due to increase in the effective dose of vaccinia virus through replication of the injected virus and/or to partial inactivation of the effective antigen through heat treatment, which resulted in lesser indurations.
The evolution of the vaccinial events at the time of the follow-up revaccination by multiple puncture method (4 months after the earlier vaccination) was studied in 4 normals, 2 lepromatous, and 3 tuberculoid individuals (Table 4) . A base line of the evolution of various events after vaccination was made by studying the time of appearance of the various events after vaccination in 15 newborns. Compared to the phasing observed in the neonates, the evolution of the vaccinial lesions was markedly accelerated in the normals and the tuberculoid leprosy patients. In both of these groups, the phasing was similar, whereas, in the lepromatous patients, the comparatively less pronounced acceleration suggested that specific delayed hypersensitivity against vaccinia virus was depressed in the lepromatous leprosy cases.
The average size of maximum vaccinial lesions was 14.0 mm, 16.0 mm, and 22.0 mm in the controls, tuberculoid cases, and lepromatous patients, respectively. The maximum vaccinial lesion appeared on 3rd day in both the controls and tuberculoid leprosy patients while it appeared on 6.5th day in lepromatous leprosy cases.
The incidence of the specific humoral antibody response studied 3 weeks after vaccination was 44, 45, and 91% in controls, tuberculoid, and lepromatous leprosy cases, respectively ( Table 5 ). The incidence of specific humoral antibody response was highest in the lepromatous cases.
Total HI antibody titers were estimated before as well as 3 weeks after vaccination in 14 controls and 19 lepromatous leprosy patients.
The total initial HI antibodies were significantly higher in the lepromatous cases than the controls. Although the initial titer of 2-mercaptoethanol-resistant (MER)-type antibodies was higher in the lepromatous leprosy cases, the difference was statistically insignificant. After 3 weeks of vaccination, increase in the total as well as the MER-type antibodies was evident in both the groups, but the changes were not statistically significant in any of them (Table  6) .
A kinetic study of total HI antibody, MER, and 2-mercaptoethanol-sensitive (MES) types of antibody titers was made in 14 controls and 7 lepromatous leprosy patients before, as well as 1, 3, and 4 weeks after, vaccination. In both the controls and the lepromatous group there occurred statistically insignificant increases in the values of total HI and MER-type antibody after vaccination. Although the changes in MERtype antibody were statistically insignificant, the appreciable increase in its value by the third and fourth weeks of vaccination was discernible (Table 7) .
A kinetic study of immunoglobulins and j8- 14 78 45 aHemagglutinaton inhibition antibody titer was studied before and 3 weeks after revaccination. Minimum titer difference of the two tubes (fourfold rise in titer) between pre-and postvaccination sera was taken as the criterion for specific humoral antibody response.
IC/IA complement before and after vaccination ( (14) have reported a relatively higher incidence of positive local reactions in the patients of lepromatous leprosy. Furthermore, in the present study vaccinia necrosum also developed in a patient of lepromatous leprosy. This finding is substantiated by a similar observation made previously (5) . As the patients of lepromatous leprosy are associated with normal humoral antibody response but poor delayed hypersensitivity reaction against vaccinia virus, it is suggested that intact cell-mediated immunity against vaccinia virus appears to be more important for the prevention of vaccinia necrosum than the normal humoral antibody response. This is further supported by the findings of O'Connell et al. (12) , who reported the development of progressive vaccinia gangrenosum in a child who showed normal humoral antibodies but failed to develop delayed hypersensitivity skin reactions.
In the past years several studies have appeared from time to time concerning the association of the smallpox vaccination with the development of lepra reaction in the leprosy patients (2, 14, 17) . Most of the studies indicate the following. Vaccination against smallpox in a leprosy population definitely seems to be a provocative factor for the precipitation of reaction in the lepromatous leprosy patients; fairly large numbers of the lepromatous leprosy patients develop a reaction for the first time following vaccination. In the present study not only have the impressions mentioned above been confirmed, but the development of the lepra reaction has been witnessed in a patient of borderline tuberculoid leprosy. Rotberg and Bechelli (17) have reported one patient each of the arthritic and neuritic types of leprosy, who also developed lepra reaction following smallpox vaccination. Although it is difficult to comment upon the genesis of reaction after vaccination in the leprosy patients, the occurrence of lepra reaction only after vaccination with live virus suggests that viremia following such vaccination (15) further lowers the already poor cell-mediated immunity and thus results in the development or acute exacerbation of lepra reaction in these patients.
The specific humoral antibody response has been the same in the tuberculoid patients as in the controls; however, in the cases of leproma- .. (18) .
It is interesting to note that, in the lepromatous patients, there was a significantly enhanced response in IgA globulin after vaccination. Whether this stimulation of serum IgA is specific to vacciinia virus or nonspecific is difficult to determine. It has been reported that the patients of lepromatous leprosy develop higher levels of complement during the active phase of reaction than in the remissive phase of reaction (19) . However, it is not possible to specify the exact mechanism of stimulation of ,BIC/IA complement observed after vaccination in these patients, and further investigations might unveil why immunoglobulin of IgA class and ,BIC/IA complement are stimulated in the immunologically deficient subjects like lepromatous leprosy patients upon being challanged with living vaccinia.
